)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Sun Pharmaceutical Industries
Sun Pharmaceutical Industries (SUNPHARMA) investor relations material
Sun Pharmaceutical Industries Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary30 Oct, 2026
Executive summary
Q2 FY27 revenue was INR 161.0bn, up 11.8% YoY; H1 revenue rose 11.0% to INR 312.836bn.
India and innovative medicines supported growth, while U.S. sales were pressured by lenalidomide erosion.
Financial highlights
Q2 EBITDA was INR 47.439bn, up 4.8% YoY, with a 29.3% margin; gross margin was 80.8%.
Q2 reported net profit was INR 19.885bn; adjusted net profit was INR 31.620bn, up 1.4% YoY. H1 adjusted net profit was INR 62.515bn, up 2.2%.
H1 EBITDA was INR 91.616bn, up 3.8%, with a 29.1% margin; H1 revenue was INR 312.836bn, up 11.0%.
Q2 R&D investment was INR 7.784bn, or 4.8% of sales; H1 investment was INR 16.048bn, or 5.1% of sales.
Outlook and guidance
FY27 revenue guidance remains unchanged from the start of the year, described as high-single-digit growth.
R&D investment is expected to ramp in H2 to meet the previously shared 6%-7% full-year guidance.
ILUMYA interventions and the psoriatic arthritis indication are expected to support more typical growth over the next few quarters; launch expenses are within budget.
Organon integration planning is progressing; the acquisition is targeted to close in Q4 FY27, subject to remaining approvals and closing conditions.
GL0034 topline data are expected in 2H CY27; Fibromun completed Phase 2 for soft-tissue sarcoma and is expected to start Phase 3.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sun Pharmaceutical Industries
- FY26 sales hit Rs 582 Bn, driven by innovation, global expansion, and strong profitability.SUNPHARMA
Investor presentation - Q1 sales up 10.1% to INR 151,836m, net profit INR 28,948m, led by India and innovation.SUNPHARMAQ1 26/27
- Achieved Rs 582 Bn sales in FY26, driven by innovation, global reach, and strong profitability.SUNPHARMAInvestor presentation
- Q4 sales up 13.6%, FY26 sales up 11.9%, with margin pressure and strong innovative growth.SUNPHARMAQ4 25/26
- Q3 FY2026 sales grew 15.1% YoY to INR 154,691 million, with net profit up 16%.SUNPHARMAQ3 25/26
- Q2 FY 2026 sales up 8.6%, net profit up 2.6%, led by strong Innovative Medicines growth.SUNPHARMAQ2 25/26
- Q1 FY26 delivered strong sales and EBITDA growth, but net profit was impacted by legal and R&D charges.SUNPHARMAQ1 25/26
- Q1 FY25 net profit jumped 40.2% on 6.3% sales growth, led by India and specialty milestones.SUNPHARMAQ1 24/25
- Full-year sales up 9% and adjusted net profit up 19%, with strong specialty growth.SUNPHARMAQ4 24/25
Next Sun Pharmaceutical Industries earnings date
Q3 26/2730 Jan, 2027
Sun Pharmaceutical Industries
Next Sun Pharmaceutical Industries earnings date
Q3 26/2730 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Sun Pharmaceutical Industries Limited operates as a pharmaceutical company. It manufactures, develops and markets generic pharmaceutical products, active pharmaceutical ingredients and intermediates, and formulation products for various dosage forms.